Food-tech
Precision fermentation, alternative proteins and the future of food.
Latest Food-tech news
Tufts Opens Shared R&D Facility for Cultivated Meat and Alternative Protein Developers - vegconomist
Read at vegconomist - the vegan business magazine →Rumors are swirling about 'lab-grown' eggs being sold in the US. Here's what to know
Read at Snopes.com →Meat: An excerpt from the new book by alternative-proteins activist Bruce Friedrich | Hindustan Times
Read at Hindustan Times →Better call soy: A Wknd interview with alternative-meat activist Bruce Friedrich | Hindustan Times
Read at Hindustan Times →Food Innovators Need Trust To Win Consumer Acceptance, New EIT Food Report Finds | Newswise
Read at Newswise →Quorn turns to blended products to kickstart recovery
Read at Foodservice Footprint →From the knowledge base
What did we learn from Big Pharma’s Q2 results?
Fierce editors break down Big Pharma’s second-quarter results, from AI and new leadership to the oral GLP-1 race and potential new blockbusters.
Regulatory tracker: J&J scores EU approval for Tecvayli-Darzalex combo
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
The Oral GLP-1 Tracker: Novo's Wegovy pill back on track as Lilly's momentum slows
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.
Lundbeck continues neuroscience evolution as CEO keeps company ‘punching above its weight’
Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a “neuroscience challenger” capable of “punching above its weight.”
Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the nature of the incident for now.
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
Pheast Therapeutics may have learned the hard way about the risks of competitors getting a glimpse of your heard-earned discoveries, but the immuno-oncology startup is so far sticking to its transparent approach.